Literature DB >> 26201405

APASL consensus statements and management algorithms for hepatitis C virus infection.

Masao Omata1,2, Tatsuo Kanda3, Ming-Lung Yu4,5, Osamu Yokosuka3, Seng-Gee Lim6, Wasim Jafri7, Ryosuke Tateishi8, Saeed S Hamid7, Wan-Long Chuang5, Anuchit Chutaputti9, Lai Wei10, Jose Sollano11, Shiv Kumar Sarin12, Jia-Horng Kao13, Geoffrey W McCaughan14.   

Abstract

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the "APASL Consensus Statements and Management Algorithms for Hepatitis C Virus Infection" in December, 2010, in order to revise "Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection (J Gastroenterol Hepatol 22:615-633, 2007)". The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Makuhari, Chiba, Japan on 19 December 2010. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations are presented in this review.

Entities:  

Keywords:  APASL; DAAs; Guideline; HCV; Treatment

Year:  2012        PMID： 26201405     DOI： 10.1007/s12072-012-9342-y

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   9.029


  257 in total

Review 1.  Infections and thalassaemia.

Authors:  Sandro Vento; Francesca Cainelli; Francesco Cesario
Journal:  Lancet Infect Dis       Date:  2006-04       Impact factor: 25.071

2.  Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.

Authors:  Michelle Martinot-Peignoux; Christiane Stern; Sarah Maylin; Marie-Pierre Ripault; Nathalie Boyer; Laurence Leclere; Corinne Castelnau; Nathalie Giuily; Ahmed El Ray; Ana-Carolina Cardoso; Rami Moucari; Tarik Asselah; Patrick Marcellin
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

3.  An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.

Authors:  Alessandra Mangia; Alexander J Thompson; Rosanna Santoro; Valeria Piazzolla; Hans L Tillmann; Keyur Patel; Kevin V Shianna; Leonardo Mottola; Daniela Petruzzellis; Donato Bacca; Vito Carretta; Nicola Minerva; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

4.  Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

Authors:  Y Shiratori; F Imazeki; M Moriyama; M Yano; Y Arakawa; O Yokosuka; T Kuroki; S Nishiguchi; M Sata; G Yamada; S Fujiyama; H Yoshida; M Omata
Journal:  Ann Intern Med       Date:  2000-04-04       Impact factor: 25.391

Review 5.  Adverse effects and other safety aspects of the hepatitis C antivirals.

Authors:  A Chutaputti
Journal:  J Gastroenterol Hepatol       Date:  2000-05       Impact factor: 4.029

6.  A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection.

Authors: 
Journal:  J Infect Dis       Date:  2005-10-28       Impact factor: 5.226

7.  Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin.

Authors:  A Potthoff; T Berg; H Wedemeyer
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

8.  Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial.

Authors:  Zachary D Goodman; Hala R Makhlouf; Lea Liu; William Balistreri; Regino P Gonzalez-Peralta; Barbara Haber; Maureen M Jonas; Parvathi Mohan; Jean P Molleston; Karen F Murray; Michael R Narkewicz; Philip Rosenthal; Lesley J Smith; Patricia R Robuck; Kathleen B Schwarz
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

9.  Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study.

Authors:  S D Ryder; W L Irving; D A Jones; K R Neal; J C Underwood
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

10.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Authors:  Mitchell L Shiffman; Fredy Suter; Bruce R Bacon; David Nelson; Hugh Harley; Ricard Solá; Stephen D Shafran; Karl Barange; Amy Lin; Ash Soman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2007-07-12       Impact factor: 91.245
View more
  83 in total

1.  Current management of patients with hepatocellular carcinoma.

Authors:  Tatsuo Kanda; Sadahisa Ogasawara; Tetsuhiro Chiba; Yuki Haga; Masao Omata; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-07-28

2.  Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?

Authors:  Tatsuo Kanda; Shingo Nakamoto; Osamu Yokosuka
Journal:  World J Virol       Date:  2015-08-12

Review 3.  Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.

Authors:  Chun-Jen Liu; Pei-Jer Chen
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

4.  Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C.

Authors:  Pn Rao; Abraham Koshy; Jacob Philip; Narayanan Premaletha; Joy Varghese; Krishnasamy Narayanasamy; Samir Mohindra; Nitin Vikas Pai; Manoj Kumar Agarwal; Ashoknanda Konar; Hasmukh B Vora
Journal:  World J Hepatol       Date:  2014-07-27

5.  Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient.

Authors:  Tatsuo Kanda; Shingo Nakamoto; Makoto Arai; Tatsuo Miyamura; Shuang Wu; Keiichi Fujiwara; Osamu Yokosuka
Journal:  Clin J Gastroenterol       Date:  2013-02-17

Review 6.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

7.  MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication.

Authors:  Wen-Wen Chou; Chung-Feng Huang; Ming-Lun Yeh; Yi-Shan Tsai; Ming-Yen Hsieh; Ching-I Huang; Jee-Fu Huang; Pei-Chien Tsai; Edward Hsi; Suh-Hang Hank Juo; Wei-Lun Tsai; Wan-Long Chuang; Ming-Lung Yu; Chia-Yen Dai
Journal:  J Mol Med (Berl)       Date:  2015-10-21       Impact factor: 4.599

Review 8.  Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment.

Authors:  E Sagnelli; T Santantonio; N Coppola; M Fasano; M Pisaturo; C Sagnelli
Journal:  Infection       Date:  2014-03-12       Impact factor: 3.553

9.  Hepatitis C virus genotypes in Myanmar.

Authors:  Nan Nwe Win; Tatsuo Kanda; Shingo Nakamoto; Osamu Yokosuka; Hiroshi Shirasawa
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

10.  Platelet count and sustained virological response in hepatitis C treatment.

Authors:  Tatsuo Kanda; Keizo Kato; Akihito Tsubota; Nobuo Takada; Takayoshi Nishino; Shigeru Mikami; Tatsuo Miyamura; Daisuke Maruoka; Shuang Wu; Shingo Nakamoto; Makoto Arai; Keiichi Fujiwara; Fumio Imazeki; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2013-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.